Aligos Therapeutics to Announce 2nd Quarter 2024 Financial Results on August 6, 2024
Aligos Therapeutics (Nasdaq: ALGS), a clinical stage biopharmaceutical company specializing in liver and viral diseases, has announced that it will release its second quarter 2024 financial results on Tuesday, August 6, 2024. The report will be made available after the close of U.S. financial markets. This announcement is significant for investors and analysts who closely follow the company's financial performance and progress in developing novel therapeutics for unmet medical needs in liver and viral diseases.
Aligos Therapeutics (Nasdaq: ALGS), una società biofarmaceutica in fase clinica specializzata in malattie del fegato e virali, ha annunciato che rilascerà i suoi risultati finanziari del secondo trimestre 2024 il martedì 6 agosto 2024. Il report sarà reso disponibile dopo la chiusura dei mercati finanziari statunitensi. Questo annuncio è significativo per gli investitori e gli analisti che seguono da vicino le performance finanziarie della società e i progressi nello sviluppo di nuovi farmaci per esigenze mediche non soddisfatte nel campo delle malattie epatiche e virali.
Aligos Therapeutics (Nasdaq: ALGS), una empresa biofarmacéutica en fase clínica especializada en enfermedades del hígado y virales, ha anunciado que publicará sus resultados financieros del segundo trimestre de 2024 el martes 6 de agosto de 2024. El informe estará disponible después del cierre de los mercados financieros en EE.UU.. Este anuncio es significativo para los inversores y analistas que siguen de cerca el desempeño financiero de la empresa y los avances en el desarrollo de nuevas terapias para necesidades médicas no satisfechas en enfermedades hepáticas y virales.
Aligos Therapeutics (Nasdaq: ALGS)는 간 질환 및 바이러스 질환 전문의 임상 단계 생명공학 회사로, 2024년 2분기 재무 보고서를 2024년 8월 6일 화요일에 발표할 것이라고 발표했습니다. 이 보고서는 미국 금융 시장의 마감 후에 제공될 것입니다. 이 발표는 회사의 재무 성과와 간 및 바이러스 질환에 대한 새로운 치료제 개발 진행 상황을 밀접하게 추적하는 투자자 및 분석가에게 중요합니다.
Aligos Therapeutics (Nasdaq: ALGS), une entreprise biopharmaceutique en phase clinique spécialisée dans les maladies du foie et les infections virales, a annoncé qu'elle publiera ses résultats financiers du deuxième trimestre 2024 le mardi 6 août 2024. Le rapport sera disponible après la fermeture des marchés financiers américains. Cette annonce est significative pour les investisseurs et les analystes qui suivent de près les performances financières de l'entreprise et les avancées dans le développement de nouvelles thérapies pour des besoins médicaux non satisfaits dans les maladies du foie et les infections virales.
Aligos Therapeutics (Nasdaq: ALGS), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf Leber- und Viruskrankheiten spezialisiert hat, hat angekündigt, dass es seine Finanzergebnisse für das zweite Quartal 2024 am Dienstag, den 6. August 2024 veröffentlichen wird. Der Bericht wird nach dem Handelsschluss der US-Finanzmärkte verfügbar sein. Diese Ankündigung ist von Bedeutung für Investoren und Analysten, die die finanzielle Leistung des Unternehmens und den Fortschritt bei der Entwicklung neuartiger Therapeutika für unbefriedigte medizinische Bedürfnisse im Bereich der Leber- und Viruskrankheiten genau verfolgen.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that it will report the Company’s second quarter 2024 financial results on Tuesday, August 6, 2024, after the close of the U.S. financial markets.
About Aligos
Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of liver and viral diseases. Aligos’ strategy is to harness the deep expertise and decades of drug development experience its team has in liver and viral diseases to discover and develop potentially best-in-class therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) and viruses with high unmet medical need such as hepatitis B and coronaviruses.
For more information, please visit www.aligos.com or follow us on LinkedIn or X.
Forward-Looking Statement
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered “forward-looking statements.” Forward-looking statements are typically, but not always, identified by the use of words such as “may,” “will,” “would,” “believe,” “intend,” “plan,” “anticipate,” “estimate,” “expect,” and other similar terminology indicating future results. Such forward looking statements are subject to substantial risks and uncertainties that could cause our development programs, future results, performance, or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include, without limitation, the risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions related to the proposed financing, risks and uncertainties inherent in the drug development process, including Aligos’ clinical-stage of development, the process of designing and conducting clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, Aligos’ ability to successfully establish, protect and defend its intellectual property, other matters that could affect the sufficiency of Aligos’ capital resources to fund operations, reliance on third parties for manufacturing and development efforts, and the impact of global events and other macroeconomic conditions on the Aligos business. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Aligos in general, see Aligos’ Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 7, 2024 and its future periodic reports to be filed or submitted with the Securities and Exchange Commission. Except as required by law, Aligos undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.
Company
Jordyn Tarazi
Vice President, Investor Relations & Corporate Communications
(650) 910-0427
jtarazi@Aligos.com
Media
Michael Fitzhugh
LifeSci Communications
(628) 234-3889
mfitzhugh@lifescicomms.com
FAQ
When will Aligos Therapeutics (ALGS) release its Q2 2024 financial results?
What is the focus of Aligos Therapeutics (ALGS)?
What is the stock symbol for Aligos Therapeutics?
